China’s SFDA Lifts Drug License, Bans Principals Over Rabies Vaccine
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has found the general manager of Dalian Jingang-Andi Bio-products responsible for the decision to add nucleic acid to the production of human rabies vaccines to lower production costs. The agency also lifted the drug maker's production license and barred its principals from involvement in the pharmaceutical industry for the next 10 years. SFDA emphasized it has not completed its investigation and could implicate still others in the scandal. Although nucleic acid is used as an adjuvant in anti-viral drugs produced in other countries, China has not approved its use in rabies vaccines. (Click here for more
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.